Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | BDKRB2 | P30411 | 8/20 | 0.37 |
| ▸ | KRAS | P01116 | 1/20 | 0.35 |
| ▸ | METAP2 | P50579 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6965159 | 0.80 | SYK (0.47) | KDM4EMAPTSMN1; SMN2BDKRB2SYK | |
| SCHEMBL6643616 | 0.77 | KDM4E (0.52) | KDM4EMAPTSMN1; SMN2METAP2MEN1 | |
| SCHEMBL659884 | 0.77 | BDKRB2 (0.45) | KDM4EMAPTSMN1; SMN2BDKRB2KRAS | |
| SCHEMBL6639297 | 0.75 | KDM4E (0.50) | KDM4EMAPTSMN1; SMN2METAP2ALDH1A1 | |
| SCHEMBL660152 | 0.74 | KDM4E (0.44) | KDM4EMAPTSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL6643288 | 0.74 | KDM4E (0.49) | KDM4EMAPTSMN1; SMN2METAP2PDE10A | |
| SCHEMBL7748595 | 0.73 | ABCB1 (0.44) | KDM4EMAPTSMN1; SMN2PDE10A | |
| SCHEMBL6643141 | 0.73 | KDM4E (0.48) | KDM4EMAPTSMN1; SMN2METAP2PDE10A | |
| SCHEMBL659122 | 0.73 | KDM4E (0.76) | KDM4EMAPTSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL2875528 | 0.72 | CRHR1 (0.55) | KDM4EMAPTSMN1; SMN2METAP2PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120283260-A1 | BRADYKININ RECEPTOR AGONISTS AND USES THEREOF TO TREAT OCULAR HYPERTENSION AND GLAUCOMA | ASTELLAS PHARMA INC. (JP) | 2012-11-08 | — | — | US | disclosed |
| US-8252793-B2 | Bradykinin receptor agonists and uses thereof to treat ocular hypertension and glaucoma | ALCON RESEARCH, LTD. (US) | 2012-08-28 | — | — | US | disclosed |
| WO-2012024419-A2 | BRADYKININ RECEPTOR AGONISTS AND USES THEREOF TO TREAT OCULAR HYPERTENSION AND GLAUCOMA | ALCON RESEARCH, LTD. (US) | 2012-02-23 | — | — | WO | disclosed |
| US-20120046285-A1 | BRADYKININ RECEPTOR AGONISTS AND USES THEREOF TO TREAT OCULAR HYPERTENSION AND GLAUCOMA | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283260-A1 | BRADYKININ RECEPTOR AGONISTS AND USES THEREOF TO TREAT OCULAR HYPERTENSION AND GLAUCOMA | BDKRB2, BDKRB1, PTGIR | KDM4E 3092/4885MAPT 2300/4885SMN1; SMN2 4878/4885 |
| US-20120046285-A1 | BRADYKININ RECEPTOR AGONISTS AND USES THEREOF TO TREAT OCULAR HYPERTENSION AND GLAUCOMA | BDKRB2, BDKRB1, PTGIR | KDM4E 3092/4885MAPT 2300/4885SMN1; SMN2 4878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.